Guidance Provided
In its Q2‑2025 earnings release, LAVA Therapeutics disclosed that it will issue formal guidance for both the upcoming third‑quarter and the full‑year 2025. Specifically, the company said it expects revenue and net‑loss figures for Q3 and the full year to be disclosed in a forthcoming update; no specific dollar amounts were disclosed in the press release itself.
Trading Implications
Because the company has not yet released concrete numbers for Q3 or the full‑year outlook, the market is currently pricing in uncertainty around LAVA’s revenue trajectory and loss‑making profile. Traders should watch for the forthcoming guidance release, as a revenue beat (or miss) relative to analyst expectations could trigger a sharp move in LVTX’s price. In the meantime, the stock remains sensitive to any additional guidance on cash burn, capital requirements, or timeline changes for its Gammabody® pipeline, which could further influence the valuation. Until the company publishes its specific revenue and net‑loss guidance, a cautious stance—monitoring the upcoming corporate update and related analyst commentary—remains prudent.